Pfizer says lung cancer drug fails two late-stage studies

[January 27, 2014]  (Reuters) — Pfizer Inc said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients with advanced non-small cell lung cancer.

The company said the drug, dacomitinib, did not show improved survival without the cancer worsening in patients when compared with another non-small cell lung cancer drug. The patients were previously treated with chemotherapy.

Pfizer said the drug did not prolong overall survival compared with a placebo in a second study.

(Reporting by Vrinda Manocha in Bangalore; editing by Savio D'Souza)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.